Tofacitinib for refractory ocular mucous membrane pemphigoid
Purpose: To report the successful use of tofacitinib in the treatment of refractory ocular mucous membrane pemphigoid (MMP). Observations: Two patients with ocular MMP presented with refractory disease after failure of multiple therapies. Treatment with tofacitinib led to durable control of conjunct...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-06-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993621001134 |
| _version_ | 1819242294229860352 |
|---|---|
| author | Hayley James Grace L. Paley Richard Brasington Philip L. Custer Todd P. Margolis Michael A. Paley |
| author_facet | Hayley James Grace L. Paley Richard Brasington Philip L. Custer Todd P. Margolis Michael A. Paley |
| author_sort | Hayley James |
| collection | DOAJ |
| description | Purpose: To report the successful use of tofacitinib in the treatment of refractory ocular mucous membrane pemphigoid (MMP). Observations: Two patients with ocular MMP presented with refractory disease after failure of multiple therapies. Treatment with tofacitinib led to durable control of conjunctival inflammation within 8 weeks and no apparent progression of sub-conjunctival fibrosis. One patient maintained absence of apparent disease activity over 16 months of follow-up. Cessation of tofacitinib in the other patient led to disease relapse which was reversed by re-initiation of therapy. Conclusions and importance: Small molecule inhibitors of Janus kinases, such as tofacitinib, may offer an effective treatment option for refractory ocular MMP. |
| first_indexed | 2024-12-23T14:37:31Z |
| format | Article |
| id | doaj.art-c1f96d7e002d4812bcc5ab45a2d4c618 |
| institution | Directory Open Access Journal |
| issn | 2451-9936 |
| language | English |
| last_indexed | 2024-12-23T14:37:31Z |
| publishDate | 2021-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Ophthalmology Case Reports |
| spelling | doaj.art-c1f96d7e002d4812bcc5ab45a2d4c6182022-12-21T17:43:18ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362021-06-0122101104Tofacitinib for refractory ocular mucous membrane pemphigoidHayley James0Grace L. Paley1Richard Brasington2Philip L. Custer3Todd P. Margolis4Michael A. Paley5Department of Ophthalmology and Visual Sciences, Washington University in Saint Louis, Center for Outpatient Health, 6th floor, 4901 Forest Park Avenue, Saint Louis, MO, 63110, USADepartment of Ophthalmology and Visual Sciences, Washington University in Saint Louis, Center for Outpatient Health, 6th floor, 4901 Forest Park Avenue, Saint Louis, MO, 63110, USADepartment of Ophthalmology and Visual Sciences, Washington University in Saint Louis, Center for Outpatient Health, 6th floor, 4901 Forest Park Avenue, Saint Louis, MO, 63110, USA; Division of Rheumatology, Department of Medicine, Washington University in Saint Louis, Center for Advanced Medicine, 5th floor Suite C, 4921 Parkview Place, Saint Louis, MO, 63110, USADepartment of Ophthalmology and Visual Sciences, Washington University in Saint Louis, Center for Outpatient Health, 6th floor, 4901 Forest Park Avenue, Saint Louis, MO, 63110, USADepartment of Ophthalmology and Visual Sciences, Washington University in Saint Louis, Center for Outpatient Health, 6th floor, 4901 Forest Park Avenue, Saint Louis, MO, 63110, USADivision of Rheumatology, Department of Medicine, Washington University in Saint Louis, Center for Advanced Medicine, 5th floor Suite C, 4921 Parkview Place, Saint Louis, MO, 63110, USA; Corresponding author. Division of Rheumatology, Department of Medicine, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8045, Saint Louis, MO, 63110, USA.Purpose: To report the successful use of tofacitinib in the treatment of refractory ocular mucous membrane pemphigoid (MMP). Observations: Two patients with ocular MMP presented with refractory disease after failure of multiple therapies. Treatment with tofacitinib led to durable control of conjunctival inflammation within 8 weeks and no apparent progression of sub-conjunctival fibrosis. One patient maintained absence of apparent disease activity over 16 months of follow-up. Cessation of tofacitinib in the other patient led to disease relapse which was reversed by re-initiation of therapy. Conclusions and importance: Small molecule inhibitors of Janus kinases, such as tofacitinib, may offer an effective treatment option for refractory ocular MMP.http://www.sciencedirect.com/science/article/pii/S2451993621001134Ocular cicatricial pemphigoidMucous membrane pemphigoidTofacitinibJAKSTATJAK inhibitor |
| spellingShingle | Hayley James Grace L. Paley Richard Brasington Philip L. Custer Todd P. Margolis Michael A. Paley Tofacitinib for refractory ocular mucous membrane pemphigoid American Journal of Ophthalmology Case Reports Ocular cicatricial pemphigoid Mucous membrane pemphigoid Tofacitinib JAK STAT JAK inhibitor |
| title | Tofacitinib for refractory ocular mucous membrane pemphigoid |
| title_full | Tofacitinib for refractory ocular mucous membrane pemphigoid |
| title_fullStr | Tofacitinib for refractory ocular mucous membrane pemphigoid |
| title_full_unstemmed | Tofacitinib for refractory ocular mucous membrane pemphigoid |
| title_short | Tofacitinib for refractory ocular mucous membrane pemphigoid |
| title_sort | tofacitinib for refractory ocular mucous membrane pemphigoid |
| topic | Ocular cicatricial pemphigoid Mucous membrane pemphigoid Tofacitinib JAK STAT JAK inhibitor |
| url | http://www.sciencedirect.com/science/article/pii/S2451993621001134 |
| work_keys_str_mv | AT hayleyjames tofacitinibforrefractoryocularmucousmembranepemphigoid AT gracelpaley tofacitinibforrefractoryocularmucousmembranepemphigoid AT richardbrasington tofacitinibforrefractoryocularmucousmembranepemphigoid AT philiplcuster tofacitinibforrefractoryocularmucousmembranepemphigoid AT toddpmargolis tofacitinibforrefractoryocularmucousmembranepemphigoid AT michaelapaley tofacitinibforrefractoryocularmucousmembranepemphigoid |